10.5. First Interpretable Results (FIR) Report A first interpretable results (FIR) report will be prepared. The exact data to be included in the FIR and its structure will be determined by the study master co -Principal Investigators, the data management/analysis and biostatistical teams (designees of SELLAS), the medical monitor(s), and the Chief Medical Officer and Head of Clinical Development of SELLAS 10.6. Final Complete Clinical Study Report (CSR) Whether the study is completed or prematurely terminated, the investigator, where applicable, should inform the institution. The investigator/institution should provide the IRB with a summary of the study’s outcome. SELLAS Life Sciences Group will ensure that both interim, as well as final complete clinical study reports are prepared (as applicable) and provided to the regulatory agency(ies) as required by the applicable regulatory requirement(s). The sponsor will also ensure that the clinical study reports in marketing applications meet the standards of the ICH harmonised tripartite guideline E3: Structure and content of clinical study reports. Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results. Upon completion of the clinical study report, the sponsor will provide the investigator with the full summary of the study results. The investigator is encouraged to share the summary results with the study patients, as appropriate. The study results will be posted on publicly available clinical trial registers . SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/ MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 232 11. Reference List Acs G, Pasha T, Zhang PJ, et al. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol.